By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Grunenthal GmbH 

Pascalstraße 6

Aachen    52076  Germany
Phone: 0241-569-1111 Fax: 0241-569-1112



Company News
Grunenthal Opens Innovation Hub In Boston As Next Step In Strategy To Drive External Innovation In Pain, Specialty Therapeutics And Medical Devices Forward 5/10/2017 8:49:16 AM
Mark Fladrich Appointed New Chief Commercial Officer (CCO) At Grunenthal 5/9/2017 10:05:19 AM
23andMe And German Pain Specialist Grunenthal Explore The Genetics Of Pain To Help Identify New Treatments For Patients 5/3/2017 11:14:50 AM
New Grunenthal CEO Forges Ahead with Treatment for Complex Regional Pain Syndrome 1/17/2017 7:08:17 AM
Grunenthal Release: Company Introduces Latin America’s Most Modern Women’s Health Products Plant 1/16/2017 7:19:13 AM
Grunenthal Receives Breakthrough Therapy Designation From U.S. FDA For Neridronic Acid For The Treatment Of CRPS 12/16/2016 9:28:35 AM
Grunenthal To Acquire Commercialization Rights Of Qutenza In Europe From Astellas Pharma Europe 12/12/2016 7:01:00 AM
Grunenthal Has Acquired US-Based Thar Pharma To Expand Its Development Portfolio Of Treatment Options For CRPS (Complex Regional Pain Syndrome), A Serious, Disabling Orphan Disease 11/17/2016 9:05:15 AM
Gabriel Baertschi Takes Office As New CEO Of Grunenthal As Of October 1, 2016 10/4/2016 10:44:20 AM
A Research Consortium Under The Direction Of Grunenthal Will Receive A Grant Of €1.5 Million From The European Fund For Regional Development And The Federal State Of North Rhein-Westphalia 9/27/2016 11:47:08 AM